Clinical trials: Persistent Corneal Epithelial Defect

Corneal Persistent Epithelial Defect

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

• Terminated
• Age: All ages
• Phase 2
• Results posted

This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…

Trial name

EXPEDE (NCT04081103)

Testing

Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle

Where

United States

Volunteers

35 people

Sponsor

Glaukos Corporation